Aripiprazole monohydrate
Based on 11 publication(s) in Google Scholar
Aripiprazole (OPC-14597) monohydrate, an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole monohydrate is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole monohydrate can be used for the research of schizophrenia and COVID19.
For research use only. We do not sell to patients.
- Purity: 99.83%
- CAS No.: 851220-85-4
- Formula: C23H29Cl2N3O3
- Molecular Weight:466.40
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Anti-Obesity Compound Library
HY-L087
-
Food-Sourced Compound Library
HY-L094
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Antidepressant Compound Library
HY-L108
-
EMA-Approved Drug Library
HY-L116
-
5-HT Receptor Compound Library
HY-L121
-
Human Metabolite Library
HY-L123
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Dopamine Receptor Compound Library
HY-L165
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
RNA Binding Bioactive Compound Library
HY-L248
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Aripiprazole monohydrate
More- Nat Neurosci. 2022 Jan;25(1):39-49. [Abstract]
- Acta Pharmacol Sin. 2021 Aug;42(8):1267-1279. [Abstract]
- Chemosphere. 2019 Jun:225:378-387. [Abstract]
- Int J Pharm. 2020 Jun 15;583:119361. [Abstract]
- CNS Neurosci Ther. 2024 May;30(5):e14739. [Abstract]
- Int J Mol Sci. 2024 Jan 14;25(2):1035. [Abstract]
- ACS Omega. 2025 Oct 17;10(42):50208-50217. [Abstract]
- Mol Pharmacol. 2023 Nov;104(5):230-238. [Abstract]
- Fundam Clin Pharmacol. 2022 Dec;36(6):976-984. [Abstract]
- Korean J Physiol Pharmacol. 2020 Nov 1;24(6):545-553. [Abstract]
- University of South Carolina. 2025.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
All 5-HT Receptor Isoforms
MoreAll Dopamine Receptor Isoforms
More
Biological Activity
|
5-HT1A Receptor |
5-HT2A Receptor |
5-HT2B Receptor |
5-HT2C Receptor |
D2 Receptor |
D3 Receptor |
D4 Receptor |
Aripiprazole monohydrate potently activates D2 receptor-mediated inhibition of cAMP accumulation[1].
Aripiprazole monohydrate shows a greater anti-inflammatory effect on TNF-α, IL-13, IL-17α and fractalkine[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:WAG/Rij rats (N = 6 per dose, 6 months, administration of a mixture of tiletamine/zolazepam)[4]
-
Dosage:0, 0.3, 1, 3 mg/kg
-
Administration:IP, 1 mL/kg, every day at 5 p.m. until the end of the experiments
-
Result:Showed some anxiolytic properties with the 1 mg/kg dose being the most active.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 851220-85-4
-
Appearance Solid
-
Molecular Weight 466.40
-
Formula C23H29Cl2N3O3
-
Color White to off-white
-
SMILES
O=C1NC2=C(C=CC(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=C2)CC1.O
-
Synonyms
OPC-14597 monohydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Neurosci
Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties. [Abstract]2022 Jan;25(1):39-49. PMID: 34887590 -
Acta Pharmacol Sin
Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats. [Abstract]2021 Aug;42(8):1267-1279. PMID: 33976388 -
Chemosphere
Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]2019 Jun:225:378-387. PMID: 30884299 -
Int J Pharm
Enhanced dissolution, permeation and oral bioavailability of aripiprazole mixed micelles: In vitro and in vivo evaluation. [Abstract]2020 Jun 15;583:119361. PMID: 32334067 -
CNS Neurosci Ther
Correlation between desynchrony of hippocampal neural activity and hyperlocomotion in the model mice of schizophrenia and therapeutic effects of aripiprazole. [Abstract]2024 May;30(5):e14739. PMID: 38702935
Aripiprazole monohydrate purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2024 May;30(5):e14739. [Abstract]
We evaluated the therapeutic effects of Aripiprazole (1 mg/kg, ip, single dose) on the electrophysiological activities of MK‐801‐treated mice.
Aripiprazole monohydrate purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2024 May;30(5):e14739. [Abstract]
In the MK-801 group, theta power was significantly reduced by Aripiprazole (1 mg/kg, ip, single dose) treatment.
Aripiprazole monohydrate purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2024 May;30(5):e14739. [Abstract]
The spontaneous spike activity of RS and FS units were significantly reduced by Aripiprazole (1 mg/kg, ip, single dose) treatment in the MK-801 group.
-
Int J Mol Sci
Differential Effects of Aripiprazole on Electroencephalography-Recorded Gamma-Band Auditory Steady-State Response, Spontaneous Gamma Oscillations and Behavior in a Schizophrenia Rat Model. [Abstract]2024 Jan 14;25(2):1035. PMID: 38256109
Aripiprazole monohydrate purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Jan 14;25(2):1035. [Abstract]
Histogram showing the average percentage of change from the vehicle/vehicle-treated group for the PLF of the gamma-band ASSR recorded in rats' global cortex following an acute administration with Aripiprazole (0 and 3 mg/kg) and MK-801 in comparison with vehicle/vehicle-treated animals and MK-801/vehicle-treated animals.
Aripiprazole monohydrate purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Jan 14;25(2):1035. [Abstract]
Horizontal activity plotted over 240 min following an acute administration with Aripiprazole (Ari) at 1, 3, 10 and 30 mg/kg in MK-801-treated rats in comparison with vehicle (Veh)/vehicle-treated, MK-801/vehicle-treated or MK-801/clozapine (Cloza)-treated rats (clozapine being used as a positive control).
-
ACS Omega
2025 Oct 17;10(42):50208-50217. PMID: 41179162 -
Mol Pharmacol
2023 Nov;104(5):230-238. PMID: 37567783 -
Fundam Clin Pharmacol
Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D2L receptor. [Abstract]2022 Dec;36(6):976-984. PMID: 35767599 -
Korean J Physiol Pharmacol
2020 Nov 1;24(6):545-553. PMID: 33093275 -
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Burris KD, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9. [Content Brief]
[2]. Davies MA, et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004 Winter;10(4):317-36. [Content Brief]
[3]. Crespo-Facorro B, et al. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. Front Pharmacol. 2021 Mar 2;12:646701. [Content Brief]
[4]. Russo E, et al. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology. 2013 Jan;64:371-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz